leflunomide has been researched along with Glomerulonephritis, Lupus in 14 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Excerpt | Relevance | Reference |
---|---|---|
"Previous studies have compared mycophenolate mofetil and azathioprine as maintenance therapy for lupus nephritis (LN)." | 9.51 | Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. ( Bao, C; Dai, L; Dai, M; Fu, Q; He, L; Li, Z; Lu, L; Sun, L; Wang, S; Wu, C; Xu, J; Zhu, X, 2022) |
"A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients." | 9.30 | Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019) |
"To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted." | 9.13 | Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. ( Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2008) |
"To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) through a meta-analysis." | 8.91 | The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis. ( Cao, H; Chen, Z; Lin, J; Liu, L; Rao, Y; Yang, H; Zhang, X, 2015) |
" In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity." | 7.78 | Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. ( He, C; Liu, S; Lu, X; Luo, P; Wu, M; Yan, Z; Yu, Y, 2012) |
"To evaluate the clinical and pathological efficacy, and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN)." | 7.75 | The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. ( Jin, XM; Li, YN; Nie, YK; Sun, Y; Yu, HM; Zhang, FS, 2009) |
"Leflunomide (LEF) is a selective inhibitor of de novo pyrimidine synthesis, currently used in the treatment of rheumatoid arthritis." | 6.71 | [Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial]. ( Bao, CD; Cai, GY; Chen, XM; Cui, TG; Hou, FF; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2005) |
"The condition of refractory lupus nephritis (LN) negatively affects the prognosis and life expectancy of the patients, posing a challenge to manage in clinical." | 5.91 | Treatment of refractory lupus nephritis using leflunomide: A prospective study. ( Chen, X; Chen, Y; Li, M; Wang, L; Zeng, X; Zhang, F; Zhang, S; Zhao, Y, 2023) |
"Previous studies have compared mycophenolate mofetil and azathioprine as maintenance therapy for lupus nephritis (LN)." | 5.51 | Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. ( Bao, C; Dai, L; Dai, M; Fu, Q; He, L; Li, Z; Lu, L; Sun, L; Wang, S; Wu, C; Xu, J; Zhu, X, 2022) |
"A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients." | 5.30 | Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019) |
" A total of 191 lupus nephritis patients were randomized to follow a combined immunosuppressive treatment (CIST) with intravenous cyclophosphamide, an oral immunosuppressive agent, namely mycophenolate mofetil, azathioprine or leflunomide, and hydroxychloroquine (n = 95), or receive intravenous cyclophosphamide alone (n = 96) for 24 weeks." | 5.30 | Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. ( An, Y; Bi, L; Deng, X; Guo, J; Li, Y; Li, Z; Lin, J; Liu, B; Liu, X; Liu, Y; Lu, X; Mei, Y; Shen, H; Sun, L; Wang, G; Wang, H; Wang, M; Wang, Y; Xiao, W; Xie, R; Xu, D; Xu, H; Yang, X; Yao, Z; Yu, F; Zhang, J; Zhang, Z; Zhao, M; Zhao, Y; Zhou, Y; Zhu, P; Zuo, X, 2019) |
"To evaluate the efficacy and safety of leflunomide in the treatment of proliferative lupus nephritis, a prospective multi-centre observational study was conducted." | 5.13 | Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. ( Cai, GY; Chen, XM; Cui, TG; Hou, FF; Jiang, ZP; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Wang, YH; Xu, FF; Yu, XQ; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2008) |
"To evaluate the clinical efficacy and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN) through a meta-analysis." | 4.91 | The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis. ( Cao, H; Chen, Z; Lin, J; Liu, L; Rao, Y; Yang, H; Zhang, X, 2015) |
" In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity." | 3.78 | Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. ( He, C; Liu, S; Lu, X; Luo, P; Wu, M; Yan, Z; Yu, Y, 2012) |
"To evaluate the clinical and pathological efficacy, and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN)." | 3.75 | The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. ( Jin, XM; Li, YN; Nie, YK; Sun, Y; Yu, HM; Zhang, FS, 2009) |
"Leflunomide (LEF) is a selective inhibitor of de novo pyrimidine synthesis, currently used in the treatment of rheumatoid arthritis." | 2.71 | [Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial]. ( Bao, CD; Cai, GY; Chen, XM; Cui, TG; Hou, FF; Li, YN; Lu, FM; Mei, CL; Ni, ZH; Qian, JQ; Wang, GB; Wang, HY; Zhang, FS; Zhao, MH; Zhao, XZ; Zhu, TY; Zou, WZ, 2005) |
"The paradigm of immunosuppressive treatment for lupus nephritis has evolved over the past few decades from corticosteroids alone to corticosteroids combined with cyclophosphamide." | 2.52 | Treatment of severe lupus nephritis: the new horizon. ( Chan, TM, 2015) |
"The condition of refractory lupus nephritis (LN) negatively affects the prognosis and life expectancy of the patients, posing a challenge to manage in clinical." | 1.91 | Treatment of refractory lupus nephritis using leflunomide: A prospective study. ( Chen, X; Chen, Y; Li, M; Wang, L; Zeng, X; Zhang, F; Zhang, S; Zhao, Y, 2023) |
"Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 8 (57.14) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Fu, Q | 1 |
Wu, C | 1 |
Dai, M | 1 |
Wang, S | 2 |
Xu, J | 1 |
Dai, L | 1 |
Li, Z | 2 |
He, L | 1 |
Zhu, X | 1 |
Sun, L | 2 |
Lu, L | 1 |
Bao, C | 1 |
Zhang, S | 1 |
Chen, Y | 1 |
Chen, X | 1 |
Zhao, Y | 2 |
Zeng, X | 1 |
Zhang, F | 1 |
Wang, L | 3 |
Li, M | 1 |
Zhang, M | 1 |
Qi, C | 1 |
Zha, Y | 1 |
Chen, J | 2 |
Luo, P | 2 |
Sun, Z | 1 |
Wan, J | 1 |
Xing, C | 1 |
Jiang, G | 1 |
Sun, M | 1 |
Chen, Q | 1 |
Li, D | 1 |
Guan, T | 1 |
Ni, Z | 1 |
An, Y | 2 |
Zhou, Y | 1 |
Bi, L | 1 |
Liu, B | 1 |
Wang, H | 1 |
Lin, J | 2 |
Xu, D | 1 |
Wang, M | 1 |
Zhang, J | 1 |
Wang, Y | 2 |
Zhu, P | 1 |
Xie, R | 1 |
Zhang, Z | 2 |
Mei, Y | 1 |
Liu, X | 1 |
Deng, X | 1 |
Yao, Z | 1 |
Xiao, W | 1 |
Shen, H | 1 |
Yang, X | 1 |
Xu, H | 1 |
Yu, F | 1 |
Wang, G | 1 |
Lu, X | 2 |
Li, Y | 3 |
Zuo, X | 1 |
Liu, Y | 1 |
Guo, J | 1 |
Zhao, M | 1 |
Chan, TM | 1 |
Hu, WX | 1 |
Chen, YH | 1 |
Bao, H | 1 |
Liu, ZZ | 1 |
Wang, SF | 1 |
Zhang, HT | 1 |
Liu, ZH | 1 |
Furie, R | 1 |
Toder, K | 1 |
Zapantis, E | 1 |
Cao, H | 1 |
Rao, Y | 1 |
Liu, L | 1 |
Yang, H | 1 |
Zhang, X | 1 |
Chen, Z | 1 |
Yang, Y | 1 |
Jia, Y | 1 |
Miao, H | 1 |
Zhou, YS | 1 |
Zhang, XY | 1 |
Wang, HY | 2 |
Cui, TG | 2 |
Hou, FF | 2 |
Ni, ZH | 2 |
Chen, XM | 2 |
Lu, FM | 2 |
Xu, FF | 1 |
Yu, XQ | 1 |
Zhang, FS | 3 |
Zhao, XZ | 2 |
Zhao, MH | 2 |
Wang, GB | 2 |
Qian, JQ | 2 |
Cai, GY | 2 |
Zhu, TY | 2 |
Wang, YH | 1 |
Jiang, ZP | 1 |
Li, YN | 3 |
Mei, CL | 2 |
Zou, WZ | 2 |
Nie, YK | 1 |
Jin, XM | 1 |
Yu, HM | 1 |
Sun, Y | 1 |
He, C | 1 |
Yan, Z | 1 |
Wu, M | 1 |
Liu, S | 1 |
Yu, Y | 1 |
Bao, CD | 1 |
Tam, LS | 1 |
Li, EK | 1 |
Wong, CK | 1 |
Lam, CW | 1 |
Li, WC | 1 |
Szeto, CC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis.[NCT01172002] | 200 participants (Anticipated) | Interventional | 2010-03-31 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 reviews available for leflunomide and Glomerulonephritis, Lupus
Article | Year |
---|---|
Treatment of severe lupus nephritis: the new horizon.
Topics: Antimalarials; Azathioprine; Biological Products; Cyclophosphamide; Cyclosporine; Humans; Immunosupp | 2015 |
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Boron Com | 2015 |
The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.
Topics: Adult; Asian People; Cyclophosphamide; Female; Humans; Isoxazoles; Leflunomide; Lupus Nephritis; Mal | 2015 |
6 trials available for leflunomide and Glomerulonephritis, Lupus
Article | Year |
---|---|
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.
Topics: Adult; Azathioprine; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hum | 2022 |
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Topics: Adult; Antibodies, Antinuclear; China; Complement C3; Cyclophosphamide; DNA; Drug Therapy, Combinati | 2019 |
Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
Topics: Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; I | 2019 |
Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study.
Topics: Adolescent; Adult; Aged; Biopsy; Disease Progression; Female; Humans; Immunosuppressive Agents; Isox | 2008 |
[Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial].
Topics: Adolescent; Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Imm | 2005 |
Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Nephritis; Male; Mid | 2006 |
5 other studies available for leflunomide and Glomerulonephritis, Lupus
Article | Year |
---|---|
Treatment of refractory lupus nephritis using leflunomide: A prospective study.
Topics: Cyclophosphamide; Humans; Leflunomide; Lupus Nephritis; Prospective Studies; Treatment Outcome | 2023 |
Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy.
Topics: Adolescent; Adult; Biopsy; Female; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide | 2009 |
Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice.
Topics: Animals; Antigen-Antibody Complex; Ascites; Cell Proliferation; Disease Models, Animal; Female; Graf | 2012 |